Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies

Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) olaparib has been approved for treatment of advanced ovarian cancer associated with BRCA1 and BRCA2 mutations. BRCA1- and BRCA2-mutated cells, which are homologous recombination (HR) deficient, are hypersensitive to PARPi through the mechanism of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Nat Commun
Autores principales: Ding, Xia, Chaudhuri, Arnab Ray, Callen, Elsa, Pang, Yan, Biswas, Kajal, Klarmann, Kimberly D., Martin, Betty K., Burkett, Sandra, Cleveland, Linda, Stauffer, Stacey, Sullivan, Teresa, Dewan, Aashish, Marks, Hanna, Tubbs, Anthony T., Wong, Nancy, Buehler, Eugen, Akagi, Keiko, Martin, Scott E., Keller, Jonathan R., Nussenzweig, André, Sharan, Shyam K.
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979061/
https://ncbi.nlm.nih.gov/pubmed/27498558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms12425
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares